Akari Therapeutics Plc (AKTX) stock
AKTXNasdaqPharmaceutical PreparationsFiscal year ends December 31
$5.70−0.81 (-12.44%)
Close on Nov 17, 2026Market cap $11.10MP/E –Yield –
Akari Therapeutics enterprise value
Enterprise value is market cap plus debt, minus cash: the value of the whole business to all its investors.
Akari Therapeutics's enterprise value was $5.35M on Nov 11, 2026, against $13.38M a year earlier. Over the last 5 years it ranged from -$593.64K to $62.47M, with a median of $13.38M.
Enterprise Value at the end of each year
| Period | Period end | Value | Change |
|---|---|---|---|
| 2026 | Nov 11, 2026 | $5.35M | -23.0% |
| 2025 | Dec 31, 2025 | $6.94M | -45.6% |
| 2024 | Dec 31, 2024 | $12.77M | +48.3% |
| 2023 | Dec 29, 2023 | $8.61M | -56.4% |
| 2022 | Dec 30, 2022 | $19.74M | -63.4% |
| 2021 | Dec 31, 2021 | $53.92M | +38.7% |
| 2020 | Dec 31, 2020 | $38.86M | +87.9% |
| 2019 | Dec 31, 2019 | $20.69M | +147.4% |
| 2018 | Dec 31, 2018 | $8.36M | -59.9% |
| 2017 | Dec 29, 2017 | $20.88M | -23.0% |
| 2016 | Dec 30, 2016 | $27.13M | -70.5% |
| 2015 | Dec 31, 2015 | $91.99M | -63.3% |
| 2014 | Dec 31, 2014 | $250.47M | – |
See a number that looks wrong?